Voriconazole Therapeutic Drug Monitoring
Top Cited Papers
Open Access
- 1 April 2006
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 50 (4), 1570-1572
- https://doi.org/10.1128/aac.50.4.1570-1572.2006
Abstract
We report on 28 patients who underwent voriconazole monitoring because of disease progression or toxicity. A relationship (P < 0.025) between disease progression and drug concentration was detected. Favorable responses were observed in 10/10 patients with concentrations above 2.05 μg/ml, while disease progressed in 44% (n = 18) of patients with concentrations below 2.05 μg/ml.Keywords
This publication has 32 references indexed in Scilit:
- Candida glabrata Fungemia in Transplant Patients Receiving Voriconazole after FluconazoleTransplantation, 2005
- Going From Genome to PillScience, 2005
- Breakthrough Zygomycosis after Voriconazole Treatment in Recipients of Hematopoietic Stem-Cell TransplantsNew England Journal of Medicine, 2004
- Polymorphisms and the Pocketbook: The Cost‐Effectiveness of Cytochrome P450 2C19 Genotyping in the Eradication of Helicobacter pylori Infection Associated with Duodenal UlcerThe Journal of Clinical Pharmacology, 2003
- Safety of Voriconazole and Dose IndividualizationClinical Infectious Diseases, 2003
- The Safety of VoriconazoleClinical Infectious Diseases, 2002
- Safety and Pharmacokinetics of Oral Voriconazole in Patients at Risk of Fungal Infection: A Dose Escalation StudyThe Journal of Clinical Pharmacology, 2002
- Clinical Significance of the Cytochrome P450 2C19 Genetic PolymorphismClinical Pharmacokinetics, 2002
- Optimisation of Itraconazole Therapy Using Target Drug ConcentrationsClinical Pharmacokinetics, 1998
- Pharmacokinetic Optimisation of Oral Antifungal TherapyClinical Pharmacokinetics, 1993